Saiweike (Pazopanib) 200mg*30 | Chia Tai Tianqing China Generic | GLT

Generic Information: Saiweike (Pazopanib) 200mg — China-Mainland

Saiweike (赛维凯) is a Chinese generic of pazopanib manufactured by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a major Chinese pharmaceutical company. It was among the first domestically approved pazopanib generics in China, receiving NMPA approval the same day as the competing first generic, and is considered bioequivalent to the originator Votrient. This listing is the 200 mg tablet (0.2 g) in a 30-tablet pack.

Chinese generic pazopanib has been included in China's national medical insurance scheme for the advanced renal cell carcinoma indication, and domestic generics like Saiweike are priced meaningfully below the imported originator. For international buyers, the China generic represents one of the most economical ways to access pazopanib without sacrificing the documented bioequivalence to the originator.

What Is Saiweike Used For?

Saiweike treats advanced renal cell carcinoma (RCC) in the first-line setting and after prior cytokine therapy, and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. As a bioequivalent generic, it delivers the same anti-angiogenic therapy as the originator at a lower cost.

How Does Saiweike Work?

Pazopanib, the active ingredient in Saiweike, is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Saiweike disrupts tumour angiogenesis, reducing the blood supply that growing tumours depend on and slowing their progression.

Indications

• Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
• Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken as four 200 mg tablets on an empty stomach (at least 1 hour before or 2 hours after a meal), swallowed whole. A 30-tablet pack provides about one week of therapy. Dose adjustment is required for hepatic impairment, and liver function and blood pressure are monitored during treatment.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Pazopanib carries a boxed warning for severe hepatotoxicity, requiring liver function monitoring before and during therapy. Hypothyroidism, haemorrhage and QT prolongation may occur, and patients should report yellowing, unusual bleeding or palpitations.

Storage

Store Saiweike below 30°C in the original pack, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT sources Saiweike through a documented China supply chain and confirms each batch against the manufacturer's details. Chinese generic pazopanib is typically priced at a small fraction of the US list price of the branded originator, making long-term anti-angiogenic therapy far more sustainable. We provide clear purchase documentation and direct contact for ongoing support.

How to Order Saiweike from GLT

To order Saiweike 200 mg (30 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is Saiweike the same as Votrient? Saiweike contains the same active ingredient (pazopanib) and is bioequivalent to Votrient; it is a Chinese generic by Nanjing Chia Tai Tianqing.

Is Saiweike reimbursed in China? Chinese generic pazopanib is included in the national medical insurance scheme for the renal cell carcinoma indication.

What is the standard dose? 800 mg once daily (four 200 mg tablets), taken on an empty stomach.